74427-22-8

Basic information

• Product Name: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE
• Synonyms: 2,2-DIFLUOROETHYL TRIFLATE;2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE;2,2-DIFLUOROETHYL TRIFLUOROMETHANESULPHONATE;2,2-Difluoroethyl trifluoromethanesulphonate 98%;2,2-Difluoroethyltrifluoromethanesulphonate98%;Trifluoromethanesulfonic acid 2,2-difluoroethyl ester;Methanesulfonic acid, 1,1,1-trifluoro-, 2,2-difluoroethyl ester
• CAS NO: 74427-22-8
• Molecular Formula: C₃H₃F₅O₃S
• Molecular Weight: 214.11
• Mol File: 74427-22-8.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 118-120°C
• Flash Point: 32.1°C
• Appearance: /
• Density: 1.6150
• Vapor Pressure: 12.4mmHg at 25°C
• Refractive Index: 1.3300-1.3340
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(74427-22-8)
• EPA Substance Registry System: 2,2-DIFLUOROETHYL TRIFLUOROMETHANESULFONATE(74427-22-8)

Safety Data

• Hazard Codes: T,Xi
• Statements: 20/21/22-36/37/38-23/24/25
• Safety Statements: 23-26-36-63-45-36/37/39
• RIDADR: 2810
• HazardClass: IRRITANT-HARMFUL
• PackingGroup: II
• Hazardous Substances Data: 74427-22-8(Hazardous Substances Data)

Usage

Uses

2,2-Difluoroethyl Triflate is used to prepare kinesin spindle protein inhibitors for treatment of taxane-refractory cancer. It is also used to synthesize MexAB-?OprM specific efflux pump inhibitors in Pseudomonas aeruginosa.

InChI:InChI=1/C3H3F5O3S/c4-2(5)1-11-12(9,10)3(6,7)8/h2H,1H2

Upstream product

• 359-13-7 difluoroethanol 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 252357-31-6 diethylacetamido-2-(2',2'-difluoroethyl) malonate 
• 1027708-07-1 methyl 3-{(2,2-difluoroethyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-5-iodo-2-thiophenecarboxylate 
• 1094568-61-2 methyl 3-{(2,2-difluoroethyl)[(trans-4-methylcyclohexyl)carbonyl]amino}-5-(4-pyrazolo[1,5-a]pyrimidin-2-ylphenyl)-2-thiophenecarboxylate 
• 1041770-41-5 (2S)-N-[1-(2,2-difluoroethyl)piperidin-4-yl]-4-(2,5-difluorophenyl)-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide 
• 1173015-74-1 isobutyric acid 3-(3-bromo-2-chloro-6-fluoro-phenyl)-1-(2,2-difluoro-ethyl)-2-oxo-1,2-dihydro-[1,8]naphthyridin-4-yl ester 
• 1194373-75-5 6-[1-(2,2-difluoroethyl)piperidin-4-yl]-4-[(2-fluoro-4-methylphenyl)amino]-7-methoxycinnoline-3-carboxamide 
• 1228088-69-4 trans-8-chloro-5-(2,2-difluoro-ethyl)-1-[4-(6-methyl-pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene 
• 1312704-50-9 5-({1-[2,4-bis(trifluoromethyl)benzyl]-1H-indazol-5-yl}methylidene)-2-{(3S)-3-[(2,2-difluoroethyl)amino]piperidin-1-yl}-1,3-thiazol-4(5H)-one 
• 1342803-58-0 trans-8-chloro-5-(2,2-difluoro-ethyl)-1-[4-(3-fluoro-pyridin-2-yl)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene 
• 1400640-64-3 (2-(4-chlorophenyl)-4-(2,2-difluoroethyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)(4-isopropoxy-3-methylphenyl)methanone 
• 1400640-03-0 (4-(2,2-difluoroethyl)-2-(p-tolyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)(4-isopropoxy-3-methylphenyl)methanone 
• 1440422-36-5 C₂₄H₂₇F₂N₅O₃S 
• 1356011-55-6 methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl} (2,2-difluoroethyl)carbamate 

Relevant articles and documents

Imidazolium-based protic ionic liquids with perfluorinated anions: Influence of chemical structure on thermal properties

The influence of the cation chemical structure, namely its side chain, on the thermal properties of imidazolium-based protic ionic liquids (PILs) with different perfluorinated anions (trifluoromethanesulfonimide (TFSI), trifluoromethanesulfonic (TFS), and trifluoroacetic (TFA) acids) was studied. With that purpose, twenty-one PILs with various alkyl (methyl-, ethyl-, butyl- and vinyl-) and fluorinated (-CH2CF3, -CH2CHF2, and -CH2CH2F) side chains were successfully synthesized. Special attention was paid to an optimization of their synthesis conditions. The structure of synthesized fluorinated and alkyl-substituted PILs was confirmed by means of nuclear magnetic resonance (NMR) analysis (1D: 1H, 19F, 13C and 2D: 1H – 19F HOESY experiments) and Fourier transform infrared (FTIR) spectroscopy, while PILs thermal behavior was determined by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) in dynamic and isothermal modes. The correlation between the PILs chemical structure and their thermal stability was established. It has been found that an increase of the length of alkyl side chain (methyl- 2F 2 3) leads to a PIL with a higher crystallinity (a higher melting point temperature) and a lower thermal stability. Thus, the best performance in terms of the thermal stability was reached for monofluorinated- (-CH2F) and butyl-TFSI PILs in liquid state: 370 °C and 400 °C, respectively, while the lowest thermal stability was obtained for trifluorinated- (-CF3) and vinyl-TFA PILs in solid state: 145 °C and 129 °C, respectively.

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

N-(2-(4-((1R,3R)-3-METHYL-2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENOXY)ETHYL)PROPAN-1-AMINE DERIVATIVES AND RELATED COMPOUNDS AS SELECTIVE DOWN-REGULATORS OF THE ESTROGEN RECEPTOR FOR TREATING CANCER

The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, pharmaceutical compositions containing them and to the compounds of Formula (I) for use as selective down-regulators of the estrogen receptor in the treatment of cell proliferative disorders, such as cancer.